Announcements Trials
Browse Landscape

Phase

Phase 2 1

Status

Completed 1

Sponsor Class

NETWORK 1

Study Type

Interventional 1

Sponsor

Cancer Type

Sarcoma 1

Conditions

Sarcoma, Synovial 1Sarcoma 1Rhabdomyosarcoma 1Neurofibrosarcoma 1Liposarcoma 1Leiomyosarcoma 1Histiocytoma, Malignant Fibrous 1Hemangiosarcoma 1Hemangiopericytoma, Malignant 1Fibrosarcoma 1

Interventions

Ifosfamide 8Doxorubicin 7Filgrastim 3brostallicin 2Trabectedin 2Radiotherapy, Conformal 2Imatinib Mesylate 2perifosine 1pegfilgrastim 1indolepropanol phosphate 1exatecan 1etoposide phosphate 1X-Rays 1Watchful Waiting 1Vincristine 1Radiotherapy 1Observation 1Mesna 1Mass Spectrometry 1Granulocyte Colony-Stimulating Factor 1Glutamine 1Etoposide 1Dactinomycin 1Cyclophosphamide 1Combined Modality Therapy 1Chromatography, High Pressure Liquid 1Chemotherapy, Adjuvant 1Biopsy 1BI 2536 1

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
NETWORK × Fibrosarcoma × exatecan × Clear all
NCT00041236 2012-07-18

Exatecan Mesylate in Treating Patients With Advanced Soft Tissue Sarcoma

European Organisation for Research and Treatment of Cancer - EORTC

Phase 2 Completed
39 enrolled
Sarcoma

Hemangiopericytoma, Malignant, Fibrosarcoma, Hemangiosarcoma, Leiomyosarcoma, Liposarcoma, Rhabdomyosarcoma, Sarcoma, Sarcoma, Synovial, Neurofibrosarcoma, Histiocytoma, Malignant Fibrous

Data powered by HemOnc (CC BY 4.0) Colophon âš¡